| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | darinaparsin | CTRPv2 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | Fumonisin B1 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | -0.0088 | 0.8 |
| mRNA | KIN001-244 | GDSC1000 | pan-cancer | AAC | 0.0086 | 0.8 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | Carboplatin | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |